Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-279 in Moderate-to-Severe Plaque Psoriasis (Phase 3)
2023-505841-22-00Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of zasocitinib in plaque psoriasis (4 arms), sponsored by Takeda. Primary endpoints: Static Physician’s Global Assessment (sPGA) 0/1 response at Week 16 and PASI-75 response at Week 16. Started Apr 2024; status: completed.
02
Drugs
zasocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2023-505841-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505841-22-00.